Review of Gardasil

Area of Science:

• Oncology
• Vaccinology
• Public Health

Background:

• Cervical cancer is a leading cause of cancer death in women globally, predominantly in developing nations lacking Pap screening infrastructure.
• Pap screening programs have significantly reduced cervical cancer incidence in industrialized countries, but HPV vaccination presents a complementary strategy, especially where screening is limited.
• The role of HPV vaccines, specifically Gardasil, in cervical cancer prevention and management warrants detailed examination, considering both benefits and risks.

Purpose of the Study:

• To review the side effects of Gardasil in the context of its population-level benefit for cervical cancer reduction in countries with established Pap screening programs.
• To present information on Gardasil's benefits, risks, and unknowns to aid individual patient decision-making regarding vaccination.
• To explore the potential of combining Gardasil vaccination with cytology screening to further reduce abnormal Pap tests and associated invasive procedures.

Main Methods:

• Review of existing literature on Gardasil efficacy, side effects, and impact on cervical cancer rates.
• Analysis of HPV vaccine benefits in populations with and without organized Pap screening programs.
• Evaluation of Gardasil's protective effects against specific HPV types (16/18 for CIN 2+, 6/11 for genital warts) and duration of protection.

Main Results:

• Gardasil provides protection against cervical intraepithelial neoplasia (CIN) 2+ lesions caused by HPV types 16/18 and genital warts caused by HPV types 6/11 for at least five years.
• In industrialized countries, the primary benefit of HPV vaccines is reducing abnormal Pap tests rather than direct cancer prevention, due to effective screening programs.
• Combining Gardasil with repeated cytology screenings may decrease the incidence of abnormal Pap tests, potentially lowering the need for colposcopies and excisional procedures.

Conclusions:

• HPV vaccination, particularly Gardasil, holds significant promise for cervical cancer prevention, especially in regions with limited access to screening.
• While Gardasil offers protection against HPV-related lesions and warts, its population-level impact on cancer reduction is most pronounced where screening is unavailable.
• In settings with robust screening, Gardasil's role may shift towards reducing abnormal screening results and associated morbidities, complementing existing public health strategies.